Adverse Drug Reactions to Oxycodone and Hydrocodone in CYP2D6 Ultrarapid Metabolizers
- 1 August 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 23 (4), 420-421
- https://doi.org/10.1097/01.jcp.0000085421.74359.60
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics, 2002
- Drug Interactions with Patient-Controlled AnalgesiaClinical Pharmacokinetics, 2002
- Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental IllnessJournal of Clinical Psychopharmacology, 2000
- Quick Onset of Severe Abdominal Pain After Codeine in an Ultrarapid Metabolizer of DebrisoquineTherapeutic Drug Monitoring, 1997
- Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependencePharmacogenetics, 1997
- Frequent occurrence of CYP2D6 gene duplication in Saudi ArabiansPharmacogenetics, 1997
- Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population*Clinical Pharmacology & Therapeutics, 1995
- Extremely Rapid Hydroxylation of DebrisoquineTherapeutic Drug Monitoring, 1985